This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Department of Defense Study in NVAF | Pradaxa® (dabigatran etexilate) Skip to main content
  • References:
  • 1. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non‑valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114(6):1290-1298.